Phase III, Multicenter, European, Randomized Trial Comparing the Combination Fludarabine Phosphate-Cyclophosphamide-Rituximab (FCR) With the Combination Fludarabine Phosphate-Cyclophosphamide-Campath (FCCam) in Previously Untreated Adults With B and C Binet Stage B-chronic Lymphoid Leukemia (B-CLL)
OBJECTIVES:
Primary
- To compare 36-month progression-free survival in patients with Binet stage B or C
B-cell chronic lymphocytic leukemia treated with first-line therapy comprising
fludarabine phosphate and cyclophosphamide and either rituximab or alemtuzumab.
Secondary
- To compare the disease-free survival, event-free survival, and overall survival of
patients treated with these regimens.
- To compare time to next treatment in patients treated with these regimens.
- To compare the overall response rate (complete response [CR] and partial response [PR])
in patients treated with these regimens.
- To compare the rate of phenotypic and molecular response in patients treated with these
regimens.
- To compare the duration of phenotypic, molecular, complete and partial responses in
patients treated with these regimens.
- To compare the response rates and survival times in biological subgroups.
- To compare the rates of treatment-related adverse effects in patients treated with
these regimens.
- To compare the quality of life of patients treated with these regimens.
- Minimal residual disease study.
OUTLINE: This is a multicenter study. Patients are stratified according to Ig mutational
status and cytogenetic abnormalities. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients receive rituximab IV on day 1 and fludarabine phosphate and
cyclophosphamide IV or orally on days 2-4 of course 1. Beginning in course 2 and for
all subsequent courses, patients receive rituximab IV on day 1 and fludarabine
phosphate and cyclophosphamide IV or orally on days 1-3.
- Arm II: Patients receive alemtuzumab subcutaneously, oral fludarabine phosphate, and
oral cyclophosphamide on days 1-3.
In both arms, treatment repeats every 28 days for 6 courses in the absence of disease
progression or unacceptable toxicity.
After completion of study treatment, patients are followed every 6 months.
Interventional
Allocation: Randomized, Masking: Open Label, Primary Purpose: Treatment
Progression-free survival at 36 months
No
Stephane Lepretre, MD
Study Chair
Centre Henri Becquerel
United States: Federal Government
CDR0000577580
NCT00564512
November 2007
Name | Location |
---|